Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1

Core Insights - Evaxion A/S is advancing its multi-component cytomegalovirus (CMV) vaccine program, EVX-V1, demonstrating protective effects of lead antigens [1][3] - The company utilizes its AI-Immunology™ platform to discover novel CMV antigens that induce specific immune responses and inhibit viral infection [2][4] - The CMV treatment market was valued at $474.6 million in 2023 and is expected to grow at a CAGR of 6.6% from 2024 to 2032, driven by increased awareness and prevalence of CMV infections [7] Company Overview - Evaxion is a clinical-stage TechBio company focused on developing AI-powered vaccines, particularly for CMV and other infectious diseases [1][10] - The company’s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen shows superior performance in neutralizing CMV compared to traditional antigens [3][9] - Evaxion is actively seeking strategic partnerships to accelerate the development of its vaccine programs [5] Industry Context - CMV infects approximately 60% to 70% of adults in developed countries and nearly 100% in developing economies, highlighting a significant medical need for effective treatments [6][8] - Despite extensive research over decades, no CMV vaccine has been approved to date, underscoring the importance of Evaxion's discoveries [9][10]